A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This multicenter, double-blind, randomized, placebo-controlled study will evaluate the effect
of dalcetrapib 600 mg on artherosclerotic disease progression, lipid profile and biomarker
profile and long-term safety profile of dalcetrapib in patients with coronary artery disease.
Atherosclerotic disease progression will be measured 1. Coronary Intravascular Ultrasound
(IVUS), Quantitative Coronary Angiography 2. Carotid B-Mode Ultrasound Intima Medial
Thickness (IMT) and total plaque volume in subjects undergoing coronary angiography who have
coronary artery disease (CAD). Patients will be randomized to receive dalcetrapib 600 mg
orally once a day or placebo. The anticipated time on study treatment will be 24 months. The
target sample size is 800-1000 patients.